Treating sickle cell disease by targeting HbS polymerization.

Although the root cause of sickle cell disease is the polymerization of hemoglobin S (HbS) to form fibers that make red cells less flexible, most drugs currently being assessed in clinical trials are targeting the downstream sequelae of this primary event. Less attention has been devoted to investigation of the multiple ways in which fiber formation can be inhibited. In this article, we describe the molecular rationale for 5 distinct approaches to inhibiting polymerization and also discuss progress with the few antipolymerization drugs currently in clinical trials.

[1]  K. Ataga,et al.  Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease , 2017, The New England journal of medicine.

[2]  C. Johnson,et al.  Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin , 2017, ACS medicinal chemistry letters.

[3]  E. Henry,et al.  Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease , 2017, Proceedings of the National Academy of Sciences.

[4]  R. Ware,et al.  Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. , 2017, Blood.

[5]  J. Simon,et al.  SCD-101: A New Anti-Sickling Drug Reduces Pain and Fatigue and Improves Red Blood Cell Shape in Peripheral Blood of Patients with Sickle Cell Disease , 2016 .

[6]  K. Bridges,et al.  Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor , 2016 .

[7]  E. Fuchs,et al.  Allogeneic stem cell transplantation for sickle cell disease , 2016, Current opinion in hematology.

[8]  G. Kato,et al.  New developments in anti‐sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? , 2016, British journal of haematology.

[9]  G. Lettre,et al.  Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies , 2016, The Lancet.

[10]  Matthew C. Canver,et al.  Customizing the genome as therapy for the β-hemoglobinopathies. , 2016, Blood.

[11]  G. Kato New insights into sickle cell disease: mechanisms and investigational therapies , 2016, Current opinion in hematology.

[12]  W. Eaton,et al.  Universality of supersaturation in protein-fiber formation , 2016, Nature Structural &Molecular Biology.

[13]  M. Telen Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. , 2016, Blood.

[14]  B. Ogutu,et al.  A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. , 2016, The New England journal of medicine.

[15]  R. Ware Optimizing hydroxyurea therapy for sickle cell anemia. , 2015, Hematology. American Society of Hematology. Education Program.

[16]  K. Dufu,et al.  GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease , 2015 .

[17]  B. Metcalf,et al.  GBT440 Demonstrates High Specificity for Red Blood Cells in Nonclinical Species , 2015 .

[18]  C. Brugnara,et al.  2015 Clinical trials update in sickle cell anemia , 2015, American journal of hematology.

[19]  E. Henry,et al.  Experiments on Hemoglobin in Single Crystals and Silica Gels Distinguish among Allosteric Models. , 2015, Biophysical journal.

[20]  K. Ataga,et al.  The trials and hopes for drug development in sickle cell disease , 2015, British journal of haematology.

[21]  Nupur K. Das,et al.  Intestine-specific Disruption of Hypoxia-inducible Factor (HIF)-2α Improves Anemia in Sickle Cell Disease* , 2015, The Journal of Biological Chemistry.

[22]  F. Ferrone The delay time in sickle cell disease after 40 years: A paradigm assessed , 2015, American journal of hematology.

[23]  M. Telen,et al.  Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. , 2015, Blood.

[24]  R. Hebbel,et al.  Sickle cell disease: renal manifestations and mechanisms , 2015, Nature Reviews Nephrology.

[25]  G. Mensah,et al.  An analysis of the NIH-supported sickle cell disease research portfolio. , 2015, Blood cells, molecules & diseases.

[26]  J. P. McCoy,et al.  Imaging flow cytometry for automated detection of hypoxia‐induced erythrocyte shape change in sickle cell disease , 2014, American journal of hematology.

[27]  Paola Sebastiani,et al.  Fetal hemoglobin in sickle cell anemia: a glass half full? , 2013, Blood.

[28]  K. Ataga,et al.  A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. , 2012, Thrombosis research.

[29]  Daniel E Bauer,et al.  Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders. , 2012, Blood.

[30]  Cong Peng,et al.  Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing , 2011, Science.

[31]  J. Tisdale,et al.  Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. , 2011, Blood.

[32]  M. Gladwin,et al.  Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. , 2011, Blood.

[33]  Eric T. Kim,et al.  How does a drug molecule find its target binding site? , 2011, Journal of the American Chemical Society.

[34]  K. Ataga,et al.  Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso‐occlusive crises in patients with sickle cell disease: a phase III randomized, placebo‐controlled, double‐blind study of the gardos channel blocker senicapoc (ICA‐17043) , 2011, British journal of haematology.

[35]  M. Gladwin,et al.  Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. , 2011, JAMA.

[36]  S. Thein,et al.  Sickle cell disease in a carrier with pyruvate kinase deficiency , 2008, Hematology.

[37]  J. Hirschhorn,et al.  Supporting Online Material Materials and Methods Figs. S1 to S10 Tables S1 to S7 References Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-specific Repressor Bcl11a , 2022 .

[38]  K. Ataga,et al.  Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. , 2008, Blood.

[39]  P. Frenette,et al.  Sickle cell disease: old discoveries, new concepts, and future promise. , 2007, The Journal of clinical investigation.

[40]  D. Abraham,et al.  5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells †,‡ , 2005, British journal of haematology.

[41]  William A Eaton,et al.  Understanding the shape of sickled red cells. , 2005, Biophysical journal.

[42]  T. Asakura,et al.  Niprisan (Nix‐0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions , 2003, British journal of haematology.

[43]  J. Stocker,et al.  ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. , 2003, Blood.

[44]  W. Eaton Linus Pauling and sickle cell disease. , 2002, Biophysical chemistry.

[45]  T. Asakura,et al.  In vitro effects of NIPRISAN (Nix‐0699): a naturally occurring, potent antisickling agent , 2002, British journal of haematology.

[46]  K. Ataga,et al.  Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. , 2001, JAMA.

[47]  A. Duits,et al.  Low adjusted‐dose acenocoumarol therapy in sickle cell disease: A pilot study , 2001, American journal of hematology.

[48]  Andrea Mozzarelli,et al.  Is cooperative oxygen binding by hemoglobin really understood? , 1999, Nature Structural Biology.

[49]  D. Bachir,et al.  A new sickle cell disease phenotype associating Hb S trait, severe pyruvate kinase deficiency (PK Conakry), and an α2 globin gene variant (Hb Conakry) , 1998, British journal of haematology.

[50]  H. Bunn Pathogenesis and treatment of sickle cell disease. , 1997, The New England journal of medicine.

[51]  M L Terrin,et al.  Hydroxyurea and Sickle Cell Anemia Clinical Utility of a Myelosuppressive “Switching” Agent , 1996, Medicine.

[52]  J. Kark,et al.  Antisickling effects of 2,3-diphosphoglycerate depletion. , 1995, Blood.

[53]  J. Hofrichter,et al.  The biophysics of sickle cell hydroxyurea therapy. , 1995, Science.

[54]  M L Terrin,et al.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.

[55]  O. Castro,et al.  Improvement of sickle cell anemia by iron‐limited erythropoiesis , 1994, American journal of hematology.

[56]  A. Schechter,et al.  Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[57]  B. Kim,et al.  2,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S. , 1990, Blood.

[58]  M. Goldberg,et al.  Treatment of sickle cell anemia with hydroxyurea and erythropoietin. , 1990, The New England journal of medicine.

[59]  J. Hofrichter,et al.  Hemoglobin S gelation and sickle cell disease. , 1987, Blood.

[60]  J. Hofrichter,et al.  Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. , 1987, Science.

[61]  E. Padlan,et al.  Refined crystal structure of deoxyhemoglobin S. II. Molecular interactions in the crystal. , 1985, The Journal of biological chemistry.

[62]  J. Hofrichter,et al.  Kinetics of sickle hemoglobin polymerization. II. A double nucleation mechanism. , 1985, Journal of molecular biology.

[63]  J. Hofrichter,et al.  Kinetics of sickle hemoglobin polymerization. I. Studies using temperature-jump and laser photolysis techniques. , 1985, Journal of molecular biology.

[64]  S. Orkin,et al.  Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. , 1984, The Journal of clinical investigation.

[65]  H. Bunn,et al.  Hemoglobin: Molecular, Genetic and Clinical Aspects , 1984 .

[66]  A. Schechter,et al.  Intracellular polymerization of sickle hemoglobin. Effects of cell heterogeneity. , 1983, The Journal of clinical investigation.

[67]  J. Greenberg,et al.  Trial of low doses of aspirin as prophylaxis in sickle cell disease. , 1983, The Journal of pediatrics.

[68]  N. Mohandas,et al.  Hydration of sickle cells using the sodium ionophore Monensin. A model for therapy. , 1982, The Journal of clinical investigation.

[69]  J. Hofrichter,et al.  Oxygen binding by sickle cell hemoglobin polymers. , 1982, Journal of molecular biology.

[70]  H. Bunn Evolution of mammalian hemoglobin function. , 1981, Blood.

[71]  F. Epstein,et al.  A study of induced hyponatremia in the prevention and treatment of sickle-cell crisis. , 1980, The New England journal of medicine.

[72]  R. Edalji,et al.  Solubilization of hemoglobin S by other hemoglobins. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[73]  J. Eaton,et al.  Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. , 1980, The New England journal of medicine.

[74]  D. Labie,et al.  β-Chain contact sites in the haemoglobin S polymer , 1980, Nature.

[75]  J. Hofrichter,et al.  Gelation of sickle cell hemoglobin in mixtures with normal adult and fetal hemoglobins. , 1979, Journal of molecular biology.

[76]  J. Hofrichter,et al.  Requirements for therapeutic inhibition of sickle haemoglobin gelation , 1978, Nature.

[77]  S. Edelstein,et al.  Three-dimensional reconstruction of the fibres of sickle cell haemoglobin , 1978, Nature.

[78]  R. Edalji,et al.  Location and bond type of intermolecular contacts in the polymerisation of haemoglobin S , 1977, Nature.

[79]  J. Hofrichter,et al.  Thermodynamics of gelation of sickle cell deoxyhemoglobin. , 1977, Journal of molecular biology.

[80]  M. Goldberg,et al.  Participation of hemoglobins A and F in polymerization of sickle hemoglobin. , 1977, The Journal of biological chemistry.

[81]  A. Minton,et al.  Analysis of non-ideal behavior in concentrated hemoglobin solutions. , 1977, Journal of molecular biology.

[82]  A. Minton Non-ideality and the thermodynamics of sickle-cell hemoglobin gelation. , 1977, Journal of molecular biology.

[83]  Z. B. Rose A procedure for decreasing the level of 2,3-bisphosphoglycerate in red cells in vitro. , 1976, Biochemical and biophysical research communications.

[84]  J. Hofrichter,et al.  Supersaturation in sickle cell hemoglobin solutions. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[85]  K. B. Ward,et al.  Crystal structure of sickle-cell deoxyhemoglobin at 5 A resolution. , 1975, Journal of molecular biology.

[86]  E. Beutler The effect of carbon monoxide on red cell life span in sickle cell disease. , 1975, Blood.

[87]  J. Hofrichter,et al.  Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[88]  H. Bunn,et al.  Asymmetrical hemoglobin hybrids. An approach to the study of subunit interactions. , 1974, Biochemistry.

[89]  E. Beutler,et al.  The effect of 2,3-DPG on the sickling phenomenon. , 1971, Blood.

[90]  J. Bertles,et al.  Hemoglobin Interaction: Modification of Solid Phase Composition in the Sickling Phenomenon , 1970, Science.

[91]  Z. B. Rose,et al.  2,3-diphosphoglycerate phosphatase from human erythrocytes. General properties and activation by anions. , 1970, The Journal of biological chemistry.

[92]  H. Bunn,et al.  Control of hemoglobin function within the red cell. , 1970, The New England journal of medicine.

[93]  H. Bunn,et al.  The interaction of 2,3-diphosphoglycerate with various human hemoglobins. , 1970, The Journal of clinical investigation.

[94]  R. Benesch,et al.  Intracellular Organic Phosphates as Regulators of Oxygen Release by Haemoglobin , 1969, Nature.

[95]  J. Changeux,et al.  ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. , 1965, Journal of molecular biology.

[96]  E. Beutler The effect of methemoglobin formation in sickle cell disease. , 1961, Journal of Clinical Investigation.

[97]  L. Pauling,et al.  Sickle cell anemia a molecular disease. , 1949, Science.

[98]  E. Ponder THE TONICITY-VOLUME RELATIONS FOR SYSTEMS CONTAINING HUMAN RED CELLS AND THE CHLORIDES OF MONOVALENT CATIONS , 1949, The Journal of general physiology.

[99]  J. Davies,et al.  Gene Therapy in a Patient with Sickle Cell Disease. , 2017, The New England journal of medicine.

[100]  M. Gladwin,et al.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. , 2007, Blood reviews.

[101]  K. Ataga,et al.  Hypercoagulability in sickle cell disease: new approaches to an old problem. , 2007, Hematology. American Society of Hematology. Education Program.

[102]  William,et al.  Delay Time of Gelation : A Possible Determinant of Clinical Severity in Sickle Cell Disease , 2005 .

[103]  John D. Martin,et al.  Glass Half Full , 2017, American Journal of Neuroradiology.

[104]  N. Enwerem,et al.  Efficacy of niprisan in the prophylactic management of patients with sickle cell disease , 2001 .

[105]  C. Wambebe,et al.  Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN in patients with Sickle Cell Disorder. , 2001, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[106]  D. Abraham,et al.  Vanillin, a potential agent for the treatment of sickle cell anemia. , 1991, Blood.

[107]  J. Hofrichter,et al.  Sickle cell hemoglobin polymerization. , 1990, Advances in protein chemistry.

[108]  J. White,et al.  Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. , 1980, The Journal of clinical investigation.

[109]  J. Hofrichter,et al.  Editorial: Delay time of gelation: a possible determinant of clinical severity in sickle cell disease. , 1976, Blood.

[110]  The Bohr Effect and Combination with Organic Phosphates , 1970, Nature.

[111]  H. Bunn,et al.  The interaction of 2,3-diphosphoglycerate with various human hemoglobins. , 1970, The Journal of clinical investigation.